967P The time of anti-PD-1 infusion improves survival outcomes by fasting conditions simulation in non-small cell lung cancer

Although PD-1 blockade represents a major breakthrough in non-small cell lung cancer (NSCLC) treatment, primary/acquired resistance frequently occurs. Fasting-mimicking conditions increase tumor immunogenicity and sensitize lung tumors to PD-1 blockade by reducing insulin-like growth factor 1 (IGF-1). We studied whether the time of anti-PD-1 infusion, which might reflect fasting conditions, may correlate with clinical outcomes in NSCLC patients.